This pipeline uses various statistical tests to identify mRNAs whose expression levels correlated to selected clinical features.
Testing the association between 18632 genes and 6 clinical features across 562 samples, statistically thresholded by Q value < 0.05, 6 clinical features related to at least one genes.
-
1 gene correlated to 'Time to Death'.
-
ZFHX4
-
183 genes correlated to 'AGE'.
-
STS , GNPNAT1 , GREB1 , DEPDC6 , SLCO1A2 , ...
-
4 genes correlated to 'PRIMARY.SITE.OF.DISEASE'.
-
SPINK8 , PTBP1 , EBI3 , LOC390110
-
1 gene correlated to 'KARNOFSKY.PERFORMANCE.SCORE'.
-
WDR60
-
28 genes correlated to 'TUMOR.STAGE'.
-
BACE1 , PTRF , FREQ , PRRG1 , GAS1 , ...
-
25 genes correlated to 'RADIATIONS.RADIATION.REGIMENINDICATION'.
-
RAPGEF1 , SNX9 , EIF4G2 , PRRX1 , ZNF507 , ...
Complete statistical result table is provided in Supplement Table 1
Clinical feature | Statistical test | Significant genes | Associated with | Associated with | ||
---|---|---|---|---|---|---|
Time to Death | Cox regression test | N=1 | shorter survival | N=1 | longer survival | N=0 |
AGE | Spearman correlation test | N=183 | older | N=73 | younger | N=110 |
PRIMARY SITE OF DISEASE | ANOVA test | N=4 | ||||
KARNOFSKY PERFORMANCE SCORE | Spearman correlation test | N=1 | higher score | N=1 | lower score | N=0 |
TUMOR STAGE | Spearman correlation test | N=28 | higher stage | N=25 | lower stage | N=3 |
RADIATIONS RADIATION REGIMENINDICATION | t test | N=25 | yes | N=18 | no | N=7 |
Time to Death | Duration (Months) | 0.3-180.2 (median=28.3) |
censored | N = 267 | |
death | N = 290 | |
Significant markers | N = 1 | |
associated with shorter survival | 1 | |
associated with longer survival | 0 |
HazardRatio | Wald_P | Q | C_index | |
---|---|---|---|---|
ZFHX4 | 1.63 | 1.961e-06 | 0.037 | 0.574 |
AGE | Mean (SD) | 59.72 (12) |
Significant markers | N = 183 | |
pos. correlated | 73 | |
neg. correlated | 110 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
STS | -0.3018 | 4.535e-13 | 8.45e-09 |
GNPNAT1 | -0.2996 | 6.839e-13 | 1.27e-08 |
GREB1 | -0.2984 | 8.545e-13 | 1.59e-08 |
DEPDC6 | -0.2979 | 9.442e-13 | 1.76e-08 |
SLCO1A2 | 0.2878 | 5.726e-12 | 1.07e-07 |
EIF4E3 | -0.2849 | 9.423e-12 | 1.76e-07 |
NPAL2 | -0.2736 | 6.483e-11 | 1.21e-06 |
C9ORF103 | -0.2731 | 6.964e-11 | 1.3e-06 |
GEMIN8 | -0.27 | 1.16e-10 | 2.16e-06 |
ODZ1 | 0.2688 | 1.416e-10 | 2.64e-06 |
PRIMARY.SITE.OF.DISEASE | Labels | N |
OMENTUM | 2 | |
OVARY | 558 | |
PERITONEUM (OVARY) | 2 | |
Significant markers | N = 4 |
ANOVA_P | Q | |
---|---|---|
SPINK8 | 9.933e-16 | 1.85e-11 |
PTBP1 | 1.007e-08 | 0.000188 |
EBI3 | 4.195e-07 | 0.00781 |
LOC390110 | 2.486e-06 | 0.0463 |
One gene related to 'KARNOFSKY.PERFORMANCE.SCORE'.
KARNOFSKY.PERFORMANCE.SCORE | Mean (SD) | 75.64 (13) |
Score | N | |
40 | 2 | |
60 | 20 | |
80 | 49 | |
100 | 7 | |
Significant markers | N = 1 | |
pos. correlated | 1 | |
neg. correlated | 0 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
WDR60 | 0.5131 | 1.561e-06 | 0.0291 |
TUMOR.STAGE | Mean (SD) | 3.05 (0.56) |
N | ||
Stage 1 | 16 | |
Stage 2 | 26 | |
Stage 3 | 431 | |
Stage 4 | 85 | |
Significant markers | N = 28 | |
pos. correlated | 25 | |
neg. correlated | 3 |
SpearmanCorr | corrP | Q | |
---|---|---|---|
BACE1 | 0.28 | 1.654e-11 | 3.08e-07 |
PTRF | 0.2454 | 4.269e-09 | 7.95e-05 |
FREQ | 0.2307 | 3.545e-08 | 0.00066 |
PRRG1 | 0.2299 | 3.972e-08 | 0.00074 |
GAS1 | 0.2222 | 1.131e-07 | 0.00211 |
PDK1 | -0.2199 | 1.541e-07 | 0.00287 |
PLCD3 | 0.2178 | 2.043e-07 | 0.00381 |
CELSR2 | 0.2135 | 3.564e-07 | 0.00664 |
NBL1 | 0.2112 | 4.791e-07 | 0.00892 |
AKAP12 | 0.2091 | 6.215e-07 | 0.0116 |
25 genes related to 'RADIATIONS.RADIATION.REGIMENINDICATION'.
RADIATIONS.RADIATION.REGIMENINDICATION | Labels | N |
NO | 3 | |
YES | 559 | |
Significant markers | N = 25 | |
Higher in YES | 18 | |
Higher in NO | 7 |
T(pos if higher in 'YES') | ttestP | Q | AUC | |
---|---|---|---|---|
RAPGEF1 | 21.41 | 1.075e-48 | 2e-44 | 0.8372 |
SNX9 | -15.64 | 3.191e-33 | 5.94e-29 | 0.7633 |
EIF4G2 | 14.34 | 1.53e-23 | 2.85e-19 | 0.7639 |
PRRX1 | 13.55 | 1.099e-19 | 2.05e-15 | 0.653 |
ZNF507 | -23.17 | 5.921e-15 | 1.1e-10 | 0.8998 |
ACTL7B | -11.46 | 7.486e-15 | 1.39e-10 | 0.7102 |
CNKSR2 | -8.77 | 1.11e-14 | 2.07e-10 | 0.7257 |
AKAP9 | 16.71 | 2.413e-14 | 4.49e-10 | 0.7895 |
CRIP2 | 9.87 | 2.984e-14 | 5.56e-10 | 0.6947 |
CALR | 7.62 | 1.079e-13 | 2.01e-09 | 0.5963 |
-
Expresson data file = OV-TP.medianexp.txt
-
Clinical data file = OV-TP.clin.merged.picked.txt
-
Number of patients = 562
-
Number of genes = 18632
-
Number of clinical features = 6
For survival clinical features, Wald's test in univariate Cox regression analysis with proportional hazards model (Andersen and Gill 1982) was used to estimate the P values using the 'coxph' function in R. Kaplan-Meier survival curves were plot using the four quartile subgroups of patients based on expression levels
For continuous numerical clinical features, Spearman's rank correlation coefficients (Spearman 1904) and two-tailed P values were estimated using 'cor.test' function in R
For multi-class clinical features (ordinal or nominal), one-way analysis of variance (Howell 2002) was applied to compare the log2-expression levels between different clinical classes using 'anova' function in R
For two-class clinical features, two-tailed Student's t test with unequal variance (Lehmann and Romano 2005) was applied to compare the log2-expression levels between the two clinical classes using 't.test' function in R
For multiple hypothesis correction, Q value is the False Discovery Rate (FDR) analogue of the P value (Benjamini and Hochberg 1995), defined as the minimum FDR at which the test may be called significant. We used the 'Benjamini and Hochberg' method of 'p.adjust' function in R to convert P values into Q values.
This is an experimental feature. The full results of the analysis summarized in this report can be downloaded from the TCGA Data Coordination Center.